1Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998, 339: 61-68.
2Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
3Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34:1225-1241.
4Kobayashi S, Ide T, Sata M, et al. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol, 2001, 34: 584-586.
5Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002,37: 259-265.
6Lok ASF, McMahon BJ. Chronic Hepatitis B. Hepatology, 2001, 34:1225-1241.
7Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology,2001,33 : 1527-1532.
8Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124 :105-117.
9van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relatlon to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut, 2003,52:420-424.
10Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology,2003,37 : 748-755.
4Mitt P, Metsvaht T, Adamson V, et al. Five-year prospectivesurveillance of nosocomial bloodstream infections in an Estonianpaediatric intensive care unit [ J ]. The Journal of hospital infection,2014, 86 (2); 95-99.
5Oladimeji AA, Temi AP, Adekunle AE, et al. Prevalence ofspontaneous bacterial peritonitis in liver cirrhosis with ascites[j]. PanAfrMedJ, 2013,15: 128.
